Atossa Genetics Appoints Carl Novina, MD, PhD as Scientific Advisor
December 21 2017 - 8:00AM
Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a
clinical-stage pharmaceutical company developing novel therapeutics
and delivery methods for breast cancer and other breast conditions
today announced that Carl Novina, MD, PhD, has been appointed as
Scientific Advisor.
Dr. Novina is one of the leading researchers in the field of
RNAi therapeutics. He is an Associate Professor of Medicine
at the Dana-Farber Cancer Institute and Harvard Medical School and
an Associate Member of the Broad Institute of Harvard and MIT. He
is currently the Principal Investigator of the Novina Lab at the
Dana-Farber Cancer Institute. His laboratory has made several
important discoveries into the biology of noncoding RNAs, their
dysregulation in cancers, and their development as biomedical
tools.
Dr. Novina received his M.D. from Columbia University, College
of Physicians and Surgeons in 2000 and his Ph.D. from Tufts
University, Sackler School of Graduate Biomedical Sciences in 1998.
His graduate work has resulted in 10 publications examining
transcriptional regulation of TATA-less promoters. In 2014 he
received the coveted National Institutes of Health Pioneer Award,
which funds bold and innovative research proposals to attack
challenging biomedical problems. Dr. Novina has established many
collaborations between industry partners and physicians to
facilitate his goal of bringing biomedical innovations from bench
to bedside.
"We are delighted to welcome Dr. Novina to our Scientific
Advisory Board which is composed of world-class experts in Breast
Cancer research,” said Dr. Steve Quay, President and CEO of Atossa
Genetics. “Dr. Novina’s immunology expertise will be invaluable as
we develop our proprietary microcatheters for delivery of CAR-T
cell therapies for the treatment of the deadlier forms of breast
cancer.”
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast
cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa, lower than anticipated rate of patient enrollment,
estimated market size of drugs under development, the safety and
efficacy of Atossa's products and services, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa’s drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.Kyle GuseCFO and General CounselPhone 206
556-3238kyle.guse@atossagenetics.com
Investor Relations Contact
Scott GordonCorProminence LLC377 Oak StreetConcourse 2Garden
City, NY 11530Phone (516) 222-2560scottg@coreIR.com
Source: Atossa Genetics Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024